Compare iShares Global Clean Energy ETF (ICLN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Sana Biotechnology Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.26 (market cap $2.27B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: iShares Global Clean Energy ETF is far larger — about 2.7× Sana Biotechnology Inc's market cap, and iShares Global Clean Energy ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Sana Biotechnology Inc for 23 Days on average.
| ICLN | SANA | |
|---|---|---|
Market Cap | $2.27B | $836.71M |
Volume | 6,845,064 | 4,507,444 |
52-Week High | $23.75 | $5.92 |
52-Week Low | $15.78 | $2.68 |
Typical Hold Time | 87 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.25, down 0.35% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 52.71 and 38.71. Recent news highlights ICLN's higher volatility and expense ratio compared to traditional energy ETFs, though geopolitical tensions and data center demand provide tailwinds for clean energy adoption.
The outlook remains challenged by competitive pressure from higher-yielding energy alternatives and significant historical drawdowns. However, global renewable energy acceleration and China's EV targets offer long-term growth potential. Key risks include fee structure disadvantages and sector volatility.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
